论文部分内容阅读
目的:比较多西紫杉醇与长春瑞滨用于治疗肺癌伴低钠血症患者的临床疗效。方法:选取2014年1月—2015年3月间诊治的肺癌合并低钠血症患者82例作为研究对象,按照患者入院顺序的单双号法将其分为观察组(n=41)与对照组(n=41);观察组患者均给予多西紫杉醇治疗,对照组患者均给予长春瑞滨治疗,比较两组患者治疗2月后总有效率和药物不良反应的发生率。结果:观察组患者治疗后的总有效率为95.12%显著高于对照组为80.49%(χ~2=4.100,P<0.05);出现不良反应的发生率为9.76%低于对照组为26.83%(χ~2=3.998,P<0.05)。结论:采用多西紫杉醇治疗肺癌伴低钠血症患者的疗效优于长春瑞滨的疗效,可更好地缓解患者的临床病症,药物安全性较高。
Objective: To compare the clinical efficacy of docetaxel and vinorelbine in the treatment of patients with lung cancer with hyponatremia. Methods: Totally 82 patients with lung cancer with hyponatremia who were diagnosed and treated between January 2014 and March 2015 were selected as study subjects. Patients were divided into observation group (n = 41) and control group (N = 41). Patients in the observation group were treated with docetaxel. Patients in the control group were treated with vinorelbine. The incidence of adverse reactions and the total effective rate after two months of treatment were compared between the two groups. Results: The total effective rate of the observation group was 95.12%, which was significantly higher than that of the control group (80.49%, χ ~ 2 = 4.100, P <0.05). The incidence of adverse reactions was 9.76%, which was lower than that of the control group (26.83% (χ ~ 2 = 3.998, P <0.05). CONCLUSION: Docetaxel is superior to vinorelbine in patients with lung cancer and hyponatremia, which can better relieve the clinical symptoms of patients and provide higher drug safety.